title: Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
authors.forename: A W A M
authors.initials: AW
authors.lastname: van Rijthoven
authors.forename: J W J
authors.initials: JW
authors.lastname: Bijlsma
authors.forename: M
authors.initials: M
authors.lastname: Canninga-van Dijk
authors.forename: R H W M
authors.initials: RH
authors.lastname: Derksen
authors.forename: J A G
authors.initials: JA
authors.lastname: van Roon
mesh_terms: D000068879:Adalimumab; D000974:Antibodies, Antinuclear / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D004247:DNA / Q000276:immunology; D005260:Female; D006801:Humans; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D004247:DNA; D000069285:Infliximab; D000068879:Adalimumab